

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

Application Number	10/750,076
Filing Date	December 31, 2003
First Named Inventor	Wolfe
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PP16022.017 (35784/271881)

Sheet 1 of 3

Rolling 1449—Do View —Header and Footer to fill in the Header which will print on every page.. You just continue to tab to create a new row.

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
BH	1	US-4,462,940	07-31-1984	Hanisch <i>et al.</i>	
	2	US-4,816,440	03-28-1989	Thomson, J.W.	
	3	US-4,894,330	01-16-1990	Hershenson <i>et al.</i>	
	4	US-4,931,543	06-05-1990	Halenbeck <i>et al.</i>	
	5	US-4,992,271	02-12-1991	Fernandes <i>et al.</i>	
	6	US-5,162,507	11-10-1992	Wolfe <i>et al.</i>	
	7	US-5,643,566	07-01-1997	Hanisch <i>et al.</i>	
	8	US-5,702,699	12-30-1997	Hanisch <i>et al.</i>	


FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
BH	9	EP 0 217 645 B1	04-08-1987	Cetus Corporation		
	10	EP 0 270 799 B1	06-15-1988	Cetus Oncology Corporation		
	11	EP 0 360 937	04-04-1990	Cetus Corporation		
	12	KR 9 306 706 B	07-23-1993	Lucky Ltd.		
	13	EP 0 215 658 B1	06-01-1994	Cetus Oncology Corporation		
	14	WO 95/31479	11-23-1995	Inhale Therapeutic Systems, Inc.		
	15	WO 98/27211	06-25-1998	Universidade Federal De Minas Gerais		
	16	WO 02/080976	10-17-2002	Chiron Corporation		

Examiner Signature	/Bruce Hissong/	Date Considered	09/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/750,076
		Filing Date	December 31, 2003
		First Named Inventor	Wolfe
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		Attorney Docket Number	PP16022.017 (35784/271881)
Sheet	2	of	3



OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
BH	17	AHN, J., <i>et al.</i> , "Investigation of Refolding Condition for Pseudomonas Fluorescens Lipase by Response Surface Methodology," <i>J. Biotechnol.</i> , 1997, pp. 151-160, Vol. 54(3).	
	18	BAM, N., <i>et al.</i> , "Molten Globule Intermediate of Recombinant Human Growth Hormone: Stabilization with Surfactants," <i>Biotechnol. Prog.</i> , 1996, pp. 801-809, Vol. 12(6).	
	19	CARPENTER, J., and J.H. CROWE, "The Mechanism of Cryoprotection of Proteins by Solutes," <i>Cryobiology</i> , 1988, pp. 244-255, Vol. 25(3).	
	20	CHARMAN, S., <i>et al.</i> , "Techniques for Assessing the Effects of Pharmaceutical Excipients on the Aggregation of Porcine Growth Hormone," <i>Pharm. Res.</i> , 1993, pp. 954-962, Vol. 10(7).	
	21	CLELAND, J., <i>et al.</i> , "Polyethylene Glycol Enhanced Protein Refolding," <i>Biotechnology</i> , 1992, pp. 1013-1019, Vol. 10(9).	
	22	DAUGHERTY, D., <i>et al.</i> , "Artificial Chaperone-Assisted Refolding of Citrate Synthase," <i>J. Biol. Chem.</i> , 1998, pp. 33961-33971, Vol. 273(51).	
	23	DRYDEN, D., and M.P. WEIR, "Evidence for an Acid-Induced Molten-Globule State in Interleukin-2; A Fluorescence and Circular Dichroism Study," <i>Biochim. Biophys. Acta</i> , 1991, pp. 94-100, Vol. 1078(1).	
	24	EDY, V., <i>et al.</i> , "Stabilisation of Mouse and Human Interferons by Acid pH Against Inactivation Due to Shaking and Guanidine Hydrochloride," <i>Proc. Soc. Exp. Biol. Med.</i> , 1974, pp. 249-253, Vol. 146(1).	
	25	EDY, V., <i>et al.</i> , "Stable and Unstable Forms of Human Fibroblast Interferon," <i>Infect. Immun.</i> , 1977, pp. 445-448, Vol. 16(2).	
	26	GAUTHIER, M., and P.A. PATSTON, "Reactivation of C1-Inhibitor Polymers by Denaturation and Gel-Filtration Chromatography," <i>Anal. Biochem.</i> , 1997, pp. 228-233, Vol. 248(2).	
	27	HOURY, W., <i>et al.</i> , "The Nature of the Initial Step in the Conformational Folding of Disulphide-Intact Ribonuclease A," <i>Nat. Struct. Biol.</i> , 1995, pp. 495-503, Vol. 2(6).	
	28	JARIWALLA, R., <i>et al.</i> , "The Reactivation of Human Interferons by Guanidine Thiocyanate," <i>Experientia</i> , 1980, pp. 1390-1391, Vol. 36(12).	

Examiner Signature	/Bruce Hissong/	Date Considered	09/13/2006
-----------------------	-----------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 04/2003)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Sheet	3	of	3	Application Number	10/750,076
				Filing Date	December 31, 2003
				First Named Inventor	Wolfe
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	PP16022.017 (35784/271881)

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
BH	29	KENDRICK, B., <i>et al.</i> , "Quantitation of the Area of Overlap Between Second-Derivative Amide I Infrared Spectra to Determine the Structural Similarity of a Protein in Different States," <i>J. Pharm. Sci.</i> , 1996, pp. 155-158, Vol. 85(2).	
	30	LEE, J.K., <i>et al.</i> , "Purification of Human Interferon- β from Recombinant <i>E. coli</i> ," <i>Korean Biochemical Journal</i> , 1990, pp. 166-171, Vol. 23(2).	
	31	MUZAMMIL, S., <i>et al.</i> , "Molten Globule-Like State of Human Serum Albumin at Low pH," <i>Eur. J. Biochem.</i> , 1999, pp. 26-32, Vol. 266(1).	
	32	PEPINSKY, R.B., "Selective Precipitation of Proteins from Guanidine Hydrochloride-Containing Solutions with Ethanol," <i>Analytical Biochemistry</i> , 1991, pp. 177-181, Vol. 195.	
	33	ROZEMA, D., and S.H. GELLMAN, "Artificial Chaperone-Assisted Refolding of Denatured-Reduced Lysozyme: Modulation of the Competition Between Renaturation and Aggregation," <i>Biochemistry</i> , 1996, pp. 15760-15771, Vol. 35(49).	
	34	ROZEMA, D., and S.H. GELLMAN, "Artificial Chaperone-Assisted Refolding of Carbonic Anhydrase B," <i>J. Biol. Chem.</i> , 1996, pp. 3478-3487, Vol. 271(7).	
	35	RUSSELL-HARDE, D., <i>et al.</i> , "The Use of Zwittergent 3-14 in the Purification of Recombinant Human Interferon- β Ser ¹⁷ (Betaseron)," <i>Journal of Interferon and Cytokine Research</i> , 1995, pp. 31-37, Vol. 15(1).	
	36	TODHUNTER, R., <i>et al.</i> , "Structure of Equine Type I and Type II Collagens," <i>Am. J. Vet. Res.</i> , 1994, pp. 425-431, Vol. 55(3).	
	37	VAN OSS, C.J., "On the Mechanism of the Cold Ethanol Precipitation Method of Plasma Protein Fractionation," <i>Journal of Protein Chemistry</i> , 1989, pp. 661-668, Vol. 8(5).	
	38	WEIR, M., <i>et al.</i> , "Micropreparative Purification of Recombinant Human Interleukin-2," <i>J. Chromatogr.</i> , 1987, pp. 209-215, Vol. 396.	
	39	XIE, Y. and D. B. WETLAUFER, "Control of Aggregation in Protein Refolding: The Temperature-Leap Tactic," <i>Protein Sci.</i> , 1996, pp. 517-523, Vol. 5(3).	

Examiner
Signature

/Bruce Hissong/

Date
Considered

09/13/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.